ASS1 activator 1
ASS1 activator 1 (Compound 10f) is a ASS1 activator with an EC50 of 1.90 μM. ASS1 activator 1 enhances the activity of ASS1 and promotes AMPK phosphorylation. ASS1 activator 1 induces cell Apoptosis. ASS1 activator 1 exhibits anticancer activity against triple-negative breast cancer, colorectal cancer and liver cancer.
For research use only. We do not sell to patients.
- Formula: C41H65N3O9
- Molecular Weight:743.97
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
In Vitro
ASS1 activator 1 potently activates recombinant ASS1 protein, with an EC50 of 1.90 μM[1].
ASS1 activator 1 (48 h) inhibits the viability of various human cancer cell lines (HT-29, HepG2, MDA-MB-231, T47D, MCF-7, SK-BR-3) with IC50 values ranging from 1.9 to 14.4 μM, while it shows low activity against normal MCF-10A mammary epithelial cells, with an IC50 of 28.5 μM[1].
ASS1 activator 1 (2-8 μM; 24 h) inhibits the migration of MDA-MB-231 triple-negative breast cancer cells in a concentration-dependent manner[1].
ASS1 activator 1 (5 μM; incubated at 37 °C until equilibrium is reached) shows a high plasma protein binding rate, with a binding rate of 98.3% in human plasma and 96.3% in rat plasma at 5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231
-
Concentration:2 μM, 4 μM, 8 μM
-
Incubation Time:18 h
-
Result:Upregulated p-AMPK levels in a concentration-dependent manner without affecting total AMPK or ASS1 levels.
Decreased SQSTM/p62 levels and increased LC3B-II levels, indicating increased autophagic flux.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | T1/2 | AUC0-t | AUC0-∞ | CL | Vz | Vss | MRT0-∞ | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 1 mg/kg | i.v. | 263 ± 34.3 ng/mL | 0.10 ± 0.00 h | 6.32 ± 0.34 h | 619 ± 79.6 ng·h/mL | 654 ± 86.3 ng·h/mL | 1.55 ± 0.21 L/h/kg | 14.1 ± 1.37 L/kg | 10.0 ± 1.30 L/kg | 6.47 ± 0.25 h | / |
| Rat[1] | 5 mg/kg | p.o. | 53.5 ± 3.61 ng/mL | 4.0 ± 0.00 h | 5.00 ± 0.69 h | 538 ± 30.8 ng·h/mL | 562 ± 41.1 ng·h/mL | / | / | / | 7.89 ± 0.72 h | 17.4 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 4−6 weeks old)[1]
-
Dosage:5 mg/kg
-
Administration:intraperitoneally; every other day; 23 days
-
Result:Reduced final tumor weights and tumor volumes significantly compared to vehicle control.
Decreased Ki67-positive cells (cell proliferation marker) significantly in tumor tissue relative to controls.
Increased LC3B levels (autophagy marker) significantly in tumor tissue relative to controls.
Caused no significant changes in mouse body weight.
Showed no pathological changes in major organs (heart, liver, spleen, lung, kidney) via H&E staining, indicating no apparent systemic toxicity.
Chemical Information
-
Molecular Weight 743.97
-
Formula C41H65N3O9
-
SMILES
C[C@@H]1O[C@@H](O[C@@H]2C[C@]3(C=C[C@]4([C@@]([H])(C(C5=O)=C[C@]4([C@@]3(C2)[H])[H])CC(O[C@H](CCC/C([C@H]5C)=N\OCCCCN6CCNCC6)CC)=O)[H])[H])[C@H](OC)[C@H](OC)[C@H]1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)